Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Zealand Pharma - Zealand Pharma - Execution framework for share buy-back program
Zealand Pharma - Execution framework for share buy-back program
GlobeNewswire

Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a…

globenewswire.com - Zealand Pharma - Zealand Pharma Announces Financial Results for the First Three Months of 2026
Zealand Pharma Announces Financial Results for the First Three Months of 2026
GlobeNewswire

Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and survodutide, and strong…

bloomberg.com - Stuart Biggs - Angelini Pharma to Buy Catalyst in Deal Worth $4.1 Billion
Angelini Pharma to Buy Catalyst in Deal Worth $4.1 Billion
Bloomberg

Italian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build a footprint in rare diseases. Angelini Pharma will pay $31.50 per share in cash for Catalyst, a 21% premium…

chron.com - BridgeBio Pharma: Q1 Earnings Snapshot
BridgeBio Pharma: Q1 Earnings Snapshot
Chron

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $164 million in its first quarter. The Palo Alto, California-based company said it had a loss of 84 cents per share. The…

globenewswire.com - Zealand Pharma - Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
GlobeNewswire

Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Financial strength to be further enhanced by…

indianexpress.com - Shubhajit Roy - Indian companies pledge to invest record $20.5 billion in US; pharma in focus
Indian companies pledge to invest record $20.5 billion in US; pharma in focus
The Indian Express

Indian companies have pledged to invest a record $20.5 billion in the United States, which includes $19.1 billion in pharmaceuticals, the US embassy said on Wednesday. The commitments were made during an investment summit in Maryland, US. According…

pymnts.com - PYMNTS - Big Pharma Runs Its Checkout Counter Through GoodRx
Big Pharma Runs Its Checkout Counter Through GoodRx
PYMNTS.com | Breaking News, Trends and Analysis

Pharma Direct, the unit that connects pharmaceutical manufacturers directly to consumers through point-of-sale pricing programs, grew 82% year over year in Q1. The platform now runs more than 125 self-pay programs. GoodRx handled approximately one…

minnpost.com - Matthew Blake - Health deserts, hospital windfalls, and a phalanx of pharma lobbyists: Inside the most controversial healthcare program you never heard of
Health deserts, hospital windfalls, and a phalanx of pharma lobbyists: Inside the most controversial healthcare program you never heard of
MinnPost

Keith Harvey is CEO of Cook Area Health Services, better known as Scenic Rivers Health, a group of nonprofit medical and dental clinics in the northeast Minnesota hinterlands. Scenic Rivers Health struggles to make the most of a mysterious federal…

marketbeat.com - Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00
MarketBeat

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its target price boosted by analysts at Citigroup from $50.00 to $66.00 in a report issued on Thursday, Benzinga reports. The firm currently has a 'buy' rating on the biopharmaceutical company's…

marketbeat.com - Ascendis Pharma A/S Q1 Earnings Call Highlights
Ascendis Pharma A/S Q1 Earnings Call Highlights
MarketBeat

Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/S NASDAQ: ASND reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare…

marketbeat.com - Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX
MarketBeat

Vanguard Group Inc. reduced its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 9.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,934,612 shares of the biopharmaceutical company's…

marketbeat.com - JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price
MarketBeat

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price objective increased by equities researchers at JPMorgan Chase & Co. from $50.00 to $58.00 in a report released on Thursday, Benzinga reports. The firm currently has an 'overweight' rating…

marketbeat.com - Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up After Strong Earnings
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up After Strong Earnings
MarketBeat

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.30, but opened at $55.36. Zealand Pharma…

newsweek.com - Alexis Kayser - Inside the fast-tracked FDA
Inside the fast-tracked FDA
Newsweek

This is a preview of the May 1 edition of Access Health— Tap here to get this newsletter delivered straight to your inbox on Thursday mornings. Good morning. This week, I attended the launch event for the West Health Accelerator at the…

seekingalpha.com - John Vincent - Tracking Tweedy Browne Portfolio - Q1 2026 Update (NYSEARCA:COPY)
Tracking Tweedy Browne Portfolio - Q1 2026 Update (NYSEARCA:COPY)
Seeking Alpha

Tweedy Browne's Q1 2026 13F portfolio rose to ~$1.26B with 93 holdings, led by CNH Industrial (17.61%). Significant portfolio concentration: top five positions (CNH, Ionis Pharma, Berkshire Hathaway, Coca-Cola FEMSA, and Alphabet) comprise ~57%.

Receive a Daily briefing on Pharma Industry News

Get Started